

Antonio Di Stasi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6169432/publications.pdf>

Version: 2024-02-01

22
papers

2,772
citations

840776

11
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

3507
citing authors

#	ARTICLE	IF	CITATIONS
1	Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 1673-1683.	27.0	1,264
2	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. <i>Blood</i> , 2009, 113, 6392-6402.	1.4	458
3	Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. <i>Blood</i> , 2007, 110, 2620-2630.	1.4	227
4	Inducible caspase-9 suicide gene controls adverse effects from alloplete T cells after haploidentical stem cell transplantation. <i>Blood</i> , 2015, 125, 4103-4113.	1.4	188
5	Improving the safety of cell therapy products by suicide gene transfer. <i>Frontiers in Pharmacology</i> , 2014, 5, 254.	3.5	165
6	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. <i>Blood</i> , 2014, 123, 3895-3905.	1.4	161
7	Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. <i>Frontiers in Immunology</i> , 2015, 6, 36.	4.8	88
8	In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0166891.	2.5	72
9	Seatbelts in CAR therapy: How Safe Are CARs?. <i>Pharmaceuticals</i> , 2015, 8, 230-249.	3.8	42
10	Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2019, 1895, 57-73.	0.9	29
11	Regulated Apoptosis of Genetically Modified Hematopoietic Stem and Progenitor Cells Via an Inducible Caspase-9 Suicide Gene in Rhesus Macaques. <i>Stem Cells</i> , 2015, 33, 91-100.	3.2	28
12	Gene Therapy to Improve Migration of T Cells to the Tumor Site. <i>Methods in Molecular Biology</i> , 2010, 651, 103-118.	0.9	9
13	Clinical-scale manufacturing of β_2 T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis. <i>Bone Marrow Transplantation</i> , 2018, 53, 766-769.	2.4	8
14	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2022, 117, 106844.	0.8	7
15	Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease. <i>Biomedicines</i> , 2017, 5, 30.	3.2	5
16	Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1345-1348.	2.4	4
17	Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1364-1372.	2.4	4
18	Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched unrelated donor transplantation. <i>American Journal of Hematology</i> , 2021, 96, E396-E398.	4.1	4

#	ARTICLE	IF	CITATIONS
19	Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 31-38.	0.4	3
20	IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100560.	1.7	2
21	Passenger Lymphocyte Syndrome and Autoimmune Hypothyroidism Following Hematopoietic Stem Cell Transplantation. <i>Case Reports in Immunology</i> , 2022, 2022, 1-6.	0.4	1
22	Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18808-e18808.	1.6	0